Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

True, true unrelated? Coexistence of Waldenstrom's macroglobulinemia and cardiac transthyretin Amyloidosis.

Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, Castillo JJ, Falk RH.

Haematologica. 2018 Apr 19. pii: haematol.2018.190405. doi: 10.3324/haematol.2018.190405. [Epub ahead of print] No abstract available.

2.

'A new staging system for cardiac transthyretin amyloidosis': is it already on the verge of obsolescence?

Singh A, Falk RH.

Eur Heart J. 2018 Jan 16. doi: 10.1093/eurheartj/ehx740. [Epub ahead of print] No abstract available.

PMID:
29351628
3.

Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.

Geller HI, Singh A, Mirto TM, Padera R, Mitchell R, Laubach JP, Falk RH.

Mayo Clin Proc. 2017 Dec;92(12):1800-1805. doi: 10.1016/j.mayocp.2017.09.016.

PMID:
29202938
4.

Apical to Base Gradient of Technetium-99m Pyrophosphate Myocardial Counts in Cardiac Amyloidosis: An Insight Into the Mechanism of Myocardial Strain Gradient, or Merely "Clouds That Mimic Land Before the Sailor's Eye?"

Falk RH, Dorbala S.

JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):243-246. doi: 10.1016/j.jcmg.2017.08.009. Epub 2017 Sep 13. No abstract available.

PMID:
28917690
5.

Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.

Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH.

JAMA. 2017 Sep 12;318(10):962-963. doi: 10.1001/jama.2017.9236. No abstract available.

6.

Novel pharmacotherapies for cardiac amyloidosis.

Alexander KM, Singh A, Falk RH.

Pharmacol Ther. 2017 Dec;180:129-138. doi: 10.1016/j.pharmthera.2017.06.011. Epub 2017 Jun 22. Review.

PMID:
28648829
7.

Left atrial structure and function in cardiac amyloidosis.

Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH, Solomon SD.

Eur Heart J Cardiovasc Imaging. 2017 Oct 1;18(10):1128-1137. doi: 10.1093/ehjci/jex097.

PMID:
28637305
8.

Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis.

Singh A, Geller HI, Falk RH.

J Am Coll Cardiol. 2017 Feb 14;69(6):757-758. doi: 10.1016/j.jacc.2016.09.987. No abstract available.

9.

Role of Imaging in Evaluating Infiltrative Heart Disease.

Divakaran S, Singh A, Collins B, Vita T, Falk RH, Di Carli MF, Blankstein R.

Curr Treat Options Cardiovasc Med. 2017 Jan;19(1):3. doi: 10.1007/s11936-017-0500-3. Review.

10.

A tale of two diagnoses: The role of noninvasive cardiovascular imaging to differentiate cardiac amyloidosis.

Kassop D, Nam JJ, Cebula BR, Shah P, Blankstein R, Falk RH, Hulten EA.

J Nucl Cardiol. 2017 Dec;24(6):2030-2032. doi: 10.1007/s12350-016-0718-6. Epub 2016 Nov 8. No abstract available.

PMID:
27826773
11.

AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Falk RH, Alexander KM, Liao R, Dorbala S.

J Am Coll Cardiol. 2016 Sep 20;68(12):1323-41. doi: 10.1016/j.jacc.2016.06.053. Review.

12.

V122I TTR Cardiac Amyloidosis in Patients of African Descent: Recognizing a Missed Disease or the Dog That Didn't Bark?

Alexander KM, Falk RH.

Circ Heart Fail. 2016 Sep;9(9). pii: e003489. doi: 10.1161/CIRCHEARTFAILURE.116.003489. No abstract available.

13.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

14.

Pondering the Prognosis and Pathology of Cardiac Amyloidosis: Answers Breed Questions.

Falk RH.

JACC Cardiovasc Imaging. 2016 Feb;9(2):139-41. doi: 10.1016/j.jcmg.2015.07.018. Epub 2016 Jan 6. No abstract available.

15.

18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.

Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, Falk RH, Di Carli MF, Dorbala S.

Circ Cardiovasc Imaging. 2015 Aug;8(8). pii: e002954. doi: 10.1161/CIRCIMAGING.114.002954.

16.

Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function.

Kwong RY, Heydari B, Abbasi S, Steel K, Al-Mallah M, Wu H, Falk RH.

Am J Cardiol. 2015 Aug 15;116(4):622-9. doi: 10.1016/j.amjcard.2015.05.021. Epub 2015 May 22.

17.

Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R.

EMBO Mol Med. 2015 May;7(5):688. doi: 10.15252/emmm.201505318. No abstract available.

18.

V122I transthyretin variant in elderly black Americans.

Quarta CC, Falk RH, Solomon SD.

N Engl J Med. 2015 Apr 30;372(18):1769. doi: 10.1056/NEJMc1503222. No abstract available.

19.

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.

Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH.

Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14.

20.

Echocardiography in cardiac amyloidosis.

Falk RH, Quarta CC.

Heart Fail Rev. 2015 Mar;20(2):125-31. doi: 10.1007/s10741-014-9466-3. Review.

PMID:
25597027
21.

The amyloidogenic V122I transthyretin variant in elderly black Americans.

Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD.

N Engl J Med. 2015 Jan 1;372(1):21-9. doi: 10.1056/NEJMoa1404852.

22.

Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R.

EMBO Mol Med. 2014 Nov;6(11):1493-507. doi: 10.15252/emmm.201404190. Erratum in: EMBO Mol Med. 2015 May;7(5):688.

23.

"Bendopnea" or "kamptopnea?": Some thoughts on terminology and mechanisms.

Falk RH.

JACC Heart Fail. 2014 Aug;2(4):425. doi: 10.1016/j.jchf.2014.03.011. No abstract available.

24.

How to image cardiac amyloidosis.

Falk RH, Quarta CC, Dorbala S.

Circ Cardiovasc Imaging. 2014 May;7(3):552-62. doi: 10.1161/CIRCIMAGING.113.001396. No abstract available.

25.

Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography.

Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, Moore SC, Falk RH.

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1652-62. doi: 10.1007/s00259-014-2787-6. Epub 2014 May 20.

PMID:
24841414
26.

Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.

Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH.

Circulation. 2014 May 6;129(18):1840-9. doi: 10.1161/CIRCULATIONAHA.113.006242. Epub 2014 Feb 21.

27.

AL amyloidosis or multiple myeloma? An important distinction.

Falk RH.

Br J Haematol. 2014 Mar;164(5):748-9. doi: 10.1111/bjh.12677. Epub 2013 Nov 22. No abstract available.

PMID:
24261595
28.

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.

Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, Seldin DC, Lavatelli F, Rognoni P, Palladini G, Merlini G, Falk RH, Semigran MJ, Dec GW Jr, Macrae CA, Liao R.

Basic Res Cardiol. 2013 Sep;108(5):378. doi: 10.1007/s00395-013-0378-5. Epub 2013 Aug 28.

29.

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, MacRae CA, Liao R.

Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H95-103. doi: 10.1152/ajpheart.00186.2013. Epub 2013 Apr 26.

30.

A transthyretin variant, Asp18Asn, associated with amyloid cardiomyopathy: a new African-American variant?

Quarta CC, Falk RH.

Amyloid. 2012 Dec;19(4):204-7. doi: 10.3109/13506129.2012.736890.

PMID:
23126592
31.

Cardiac amyloidosis.

Quarta CC, Kruger JL, Falk RH.

Circulation. 2012 Sep 18;126(12):e178-82. doi: 10.1161/CIRCULATIONAHA.111.069195. No abstract available.

32.

Quantification of extracellular matrix expansion by CMR in infiltrative heart disease.

Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY.

JACC Cardiovasc Imaging. 2012 Sep;5(9):897-907. doi: 10.1016/j.jcmg.2012.04.006.

33.

Longitudinal strain imaging in light-chain cardiac amyloidosis: can it help to refine the approach to treatment?

Quarta CC, Falk RH.

J Am Coll Cardiol. 2012 Sep 18;60(12):1077-8. doi: 10.1016/j.jacc.2012.06.007. Epub 2012 Aug 8. No abstract available.

34.

Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR.

Am Heart J. 2012 Aug;164(2):222-228.e1. doi: 10.1016/j.ahj.2012.04.015.

PMID:
22877808
35.

Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques?

Falk RH.

Amyloid. 2012 Jun;19 Suppl 1:68-70. doi: 10.3109/13506129.2012.674074. Review.

PMID:
22620969
36.

Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide.

Philippakis AA, Falk RH.

Circulation. 2012 Apr 10;125(14):1821-4. doi: 10.1161/CIRCULATIONAHA.111.064246. No abstract available.

37.

Dronedarone in high-risk permanent atrial fibrillation.

Falk RH.

N Engl J Med. 2012 Mar 22;366(12):1159-60; author reply 1161. doi: 10.1056/NEJMc1200742. No abstract available.

PMID:
22435379
38.

Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature.

Girouard SD, Falk RH, Rennke HG, Merola JF.

Dermatol Online J. 2012 Jan 15;18(1):2. Review.

PMID:
22301039
39.

Letter by Falk regarding article, "An unusual heart failure: cardiac amyloidosis due to light chain myeloma".

Falk RH.

Circulation. 2011 Nov 15;124(20):e534; author reply e535. doi: 10.1161/CIRCULATIONAHA.111.046953. No abstract available.

40.

Current perspectives on cardiac amyloidosis.

Guan J, Mishra S, Falk RH, Liao R.

Am J Physiol Heart Circ Physiol. 2012 Feb 1;302(3):H544-52. doi: 10.1152/ajpheart.00815.2011. Epub 2011 Nov 4. Review.

41.

Cardiac amyloidosis: a treatable disease, often overlooked.

Falk RH.

Circulation. 2011 Aug 30;124(9):1079-85. doi: 10.1161/CIRCULATIONAHA.110.010447. No abstract available.

42.

Myxoma, dyspnoea, tinnitus, scoliosis, and alopecia.

Rajab TK, Shekar P, Falk RH.

Lancet. 2011 Apr 16;377(9774):1378. doi: 10.1016/S0140-6736(11)60328-0. No abstract available.

PMID:
21497702
43.

Pulmonary venous isolation for atrial fibrillation in severe systolic heart failure: more questions than answers?

Falk RH.

Heart. 2011 May;97(9):687-8. doi: 10.1136/hrt.2010.214866. Epub 2011 Jan 30. No abstract available.

PMID:
21282135
44.

Pursuing an underdiagnosed disease: a simple imaging test for increasing suspicion of cardiac amyloidosis.

Falk RH, Dorbala S.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):467-9. doi: 10.1007/s00259-011-1727-y. No abstract available.

PMID:
21267559
45.

Amyloid diseases of the heart: assessment, diagnosis, and referral.

Dubrey SW, Hawkins PN, Falk RH.

Heart. 2011 Jan;97(1):75-84. doi: 10.1136/hrt.2009.190405. Review. No abstract available.

PMID:
21148582
46.

Clinical problem-solving. A heavy heart.

Miller AL, Falk RH, Levy BD, Loscalzo J.

N Engl J Med. 2010 Oct 7;363(15):1464-9. doi: 10.1056/NEJMcps0804916. No abstract available.

PMID:
20925549
47.

Prognostic significance of strain Doppler imaging in light-chain amyloidosis.

Koyama J, Falk RH.

JACC Cardiovasc Imaging. 2010 Apr;3(4):333-42. doi: 10.1016/j.jcmg.2009.11.013.

48.

Amyloid heart disease.

Dubrey SW, Falk RH.

Br J Hosp Med (Lond). 2010 Feb;71(2):76-82.

PMID:
20220694
49.

Amyloid heart disease.

Falk RH, Dubrey SW.

Prog Cardiovasc Dis. 2010 Jan-Feb;52(4):347-61. doi: 10.1016/j.pcad.2009.11.007. Review. Erratum in: Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):445-7.

PMID:
20109604
50.

Diagnosis and management of cardiac sarcoidosis.

Dubrey SW, Falk RH.

Prog Cardiovasc Dis. 2010 Jan-Feb;52(4):336-46. doi: 10.1016/j.pcad.2009.11.010. Review.

PMID:
20109603

Supplemental Content

Support Center